The people who deserve extra attention usually include: Patients with a known history of diabetic retinopathy Patients with diabetic macular edema Patients with recently worsening retinopathy Patients with poor baseline glucose control who may experience a large A1c drop Patients starting semaglutide while already under retina treatment Patients with multiple high-risk features such as kidney disease, hypertension, or long-standing diabetes In contrast, a patient with type 2 diabetes, no known retinopathy, and a recent normal dilated exam may still need routine follow-upbut often not the same level of concern as someone with active retinal disease
The prolonged half-life of GLP-1 analogs is achieved through several mechanisms, such as delayed absorption from the subcutaneous injection site, albumin binding, which shields the molecule from enzymatic degradation by DPP-4, and reduced renal clearance
The first agent in this class was approved in 2005 for type 2 diabetes, and ongoing studies continue to look at their broader applications, long-term benefits and safety profile
While their clinical benefits are well established, their growing use raises important considerations for dietary intake, nutritional status, and long-term health outcomes
As a leader on advancing sound science and transparency in chemical regulation, Congressman Grothman's engagement on these issues is greatly valued
